ENMD - EntreMed, Inc. (NASDAQ:ENMD)
- Creatore Discussione BigNick
- Data di inizio
-
ANNUNCIO: 46° Edizione del settimanale "Le opportunità di Borsa" dedicato ai consulenti finanziari ed esperti di borsa.
Settimana tutto sommato positiva per le principali piazze internazionali che proseguono così il rimbalzo dai minimi di ottobre. Novembre sarà ricordato come uno dei mesi migliori nella storia più o meno recente dei mercati finanziari. Il calo dei rendimenti, con un ulteriore irripidimento delle curve, ha portato gli indici obbligazionari globali a registrare le migliori performance mensili dalla Grande Crisi Finanziaria, ovvero da dicembre 2008. Per l’azionario globale, invece, è stato il miglior rally mensile dal 2020. L’impulso è stato fornito anche dai dati sull’inflazione nell’area euro, che hanno rafforzato la tendenza ad anticipare la tempistica di un primo taglio dei tassi da parte della Bce già a partire dal 2024. Per continuare a leggere visita il link -
ANNUNCIO: Segui le NewsLetter di Borse.it.
Al via la Newsletter di Borse, con tutte le notizie quotidiane sui mercati finanziari. Iscriviti per rimanere aggiornato con le ultime News di settore, quotazioni e titoli del momento.
Per iscriverti visita questo link.
BigNick
Siamo solo noi
- Registrato
- 10/7/01
- Messaggi
- 10.951
- Punti reazioni
- 908
Re: adesso...
non tutti assieme se no mi confondete !!
va beh, vado avanti da solo, per chi dovesse leggere sappia che Mercoledì mattina 14 Maggio renderanno pubblici i dati trimestrali, qundi occhio a prendere posizioni perche si può rimanere in braghe di tela (..e non è bello !)
appena Prophet JavaChart torna a funzionare posto un grafico aggiornato
bye
X Lucky: dove sei finito ? sei andato a festeggiare il 100% su TRPH !!
ciao
BigNick
Scritto da BigNick
quasi quasi sarebbe da provare, titolo rischiosissimo pero'
chi mi da un parere ?
BigNick
non tutti assieme se no mi confondete !!
va beh, vado avanti da solo, per chi dovesse leggere sappia che Mercoledì mattina 14 Maggio renderanno pubblici i dati trimestrali, qundi occhio a prendere posizioni perche si può rimanere in braghe di tela (..e non è bello !)
appena Prophet JavaChart torna a funzionare posto un grafico aggiornato
bye
X Lucky: dove sei finito ? sei andato a festeggiare il 100% su TRPH !!
ciao
BigNick
BigNick
Siamo solo noi
- Registrato
- 10/7/01
- Messaggi
- 10.951
- Punti reazioni
- 908
ok
non preoccuparti ci sono qui io a ricordartelo !!
oggi potrebbe essere un giorno giusto per comprare,
proprio oggi ENMD uscirà dall indice biotecnologico del Nasdaq,
e magari ci sarà qualche pezzo grosso che venderà
vedremo.
BigNick
http://biz.yahoo.com/prnews/030509/dcf040_1.html
Semi-Annual Changes to the NASDAQ Biotechnology Index
Friday May 9, 6:30 pm ET
NEW YORK, May 9 /PRNewswire/ -- The Nasdaq Stock Market, Inc. (NASDAQ) announced today the results of the semi-annual re-ranking of the NASDAQ Biotechnology Index® (Nasdaq: NBI - News), which will become effective with the market open on Monday, May 19, 2003.
ADVERTISEMENT
The following issues will be added to the Index: Corixa Corporation (Nasdaq: CRXA - News); ID Biomedical Corporation (Nasdaq: IDBE - News), MGI Pharma Inc. (Nasdaq: MOGN - News); PRAECIS PHARMACEUTICALS INCORPORATED (Nasdaq: PRCS - News); SciClone Pharmaceuticals, Inc. (Nasdaq: SCLN - News); and XOMA Ltd. (Nasdaq: XOMA - News).
Corixa Corporation, headquartered in Seattle, Washington, is a developer of immunotherapeutics for the treatment and prevention of cancer, infectious diseases and autoimmune diseases. Corixa currently has multiple programs in clinical development, including several product candidates that have advanced to or through late stage clinical trials.
ID Biomedical Corporation, headquartered in Vancouver, British Columbia, is focused on the development of proprietary subunit vaccine products, including those based on its Proteosome(TM) platform intranasal adjuvant/delivery technology. The company has also developed a proprietary genomics analysis system, Cycling Probe(TM) Technology. The Company's lead products in clinical development are the FluINsure(TM) intranasal influenza (flu) vaccine and the StreptAvax(TM) group A streptococcal vaccine. Additionally, the Company has a number of vaccines in preclinical development.
MGI PHARMA, Inc., headquartered in Bloomington, Minnesota, is an oncology- focused biopharmaceutical company that acquires, develops and commercializes proprietary products that address the unmet needs of cancer patients. The Company directly markets its products in the U.S. including Salagen® Tablets (pilocarpine hydrochloride) and Hexalen® (altretamine) capsules and collaborates with various alliances in international markets.
PRAECIS PHARMACEUTICALS INCORPORATED, headquartered in Waltham, Massachusetts, is focused on the discovery and development of pharmaceutical products using its proprietary LEAP(TM) (Ligand Evolution to Active Pharmaceuticals) technology. PRAECIS employed LEAP(TM) in the development of Plenaxis(TM), its candidate for the treatment of hormonally responsive advanced prostate cancer and endometriosis.
SciClone Pharmaceuticals, headquartered in San Mateo, California, is engaged in the development of therapeutics to treat life-threatening diseases. Its lead product ZADAXIN is in several late-stage clinical trials for hepatitis B & C, malignant melanoma and liver cancer. In addition to ZADAXIN, the company's drug development opportunities include SCV-07, a potentially orally available therapy to treat viral and infectious diseases, and products to address the protein-based disorder that causes cystic fibrosis.
XOMA Ltd., headquartered in Berkeley, California, develops and manufactures antibody and other protein-based biopharmaceuticals for disease targets that include cancer, immunological and inflammatory disorders, and infectious diseases. XOMA's programs include collaborations relating Raptiva(TM) antibody for psoriasis, rheumatoid arthritis, psoriatic arthritis and other indications; NEUPREX (R)(rBPI21) for Crohn's disease and other indications; and on two biotherapeutic agents, CAB2 and MLN01, for certain vascular inflammation indications.
As a result of the re-ranking, Emisphere Technologies, Inc. (EMIS) EntreMed, Inc. (ENMD) will be removed from the Index
Scritto da Luciano
ci sono ci sono ma sai che il mio tempo libero è davvero esiguo
se riesco gli dò un occhiata dopo sempre che me ne ricordi
ciao
non preoccuparti ci sono qui io a ricordartelo !!
oggi potrebbe essere un giorno giusto per comprare,
proprio oggi ENMD uscirà dall indice biotecnologico del Nasdaq,
e magari ci sarà qualche pezzo grosso che venderà
vedremo.
BigNick
http://biz.yahoo.com/prnews/030509/dcf040_1.html
Semi-Annual Changes to the NASDAQ Biotechnology Index
Friday May 9, 6:30 pm ET
NEW YORK, May 9 /PRNewswire/ -- The Nasdaq Stock Market, Inc. (NASDAQ) announced today the results of the semi-annual re-ranking of the NASDAQ Biotechnology Index® (Nasdaq: NBI - News), which will become effective with the market open on Monday, May 19, 2003.
ADVERTISEMENT
The following issues will be added to the Index: Corixa Corporation (Nasdaq: CRXA - News); ID Biomedical Corporation (Nasdaq: IDBE - News), MGI Pharma Inc. (Nasdaq: MOGN - News); PRAECIS PHARMACEUTICALS INCORPORATED (Nasdaq: PRCS - News); SciClone Pharmaceuticals, Inc. (Nasdaq: SCLN - News); and XOMA Ltd. (Nasdaq: XOMA - News).
Corixa Corporation, headquartered in Seattle, Washington, is a developer of immunotherapeutics for the treatment and prevention of cancer, infectious diseases and autoimmune diseases. Corixa currently has multiple programs in clinical development, including several product candidates that have advanced to or through late stage clinical trials.
ID Biomedical Corporation, headquartered in Vancouver, British Columbia, is focused on the development of proprietary subunit vaccine products, including those based on its Proteosome(TM) platform intranasal adjuvant/delivery technology. The company has also developed a proprietary genomics analysis system, Cycling Probe(TM) Technology. The Company's lead products in clinical development are the FluINsure(TM) intranasal influenza (flu) vaccine and the StreptAvax(TM) group A streptococcal vaccine. Additionally, the Company has a number of vaccines in preclinical development.
MGI PHARMA, Inc., headquartered in Bloomington, Minnesota, is an oncology- focused biopharmaceutical company that acquires, develops and commercializes proprietary products that address the unmet needs of cancer patients. The Company directly markets its products in the U.S. including Salagen® Tablets (pilocarpine hydrochloride) and Hexalen® (altretamine) capsules and collaborates with various alliances in international markets.
PRAECIS PHARMACEUTICALS INCORPORATED, headquartered in Waltham, Massachusetts, is focused on the discovery and development of pharmaceutical products using its proprietary LEAP(TM) (Ligand Evolution to Active Pharmaceuticals) technology. PRAECIS employed LEAP(TM) in the development of Plenaxis(TM), its candidate for the treatment of hormonally responsive advanced prostate cancer and endometriosis.
SciClone Pharmaceuticals, headquartered in San Mateo, California, is engaged in the development of therapeutics to treat life-threatening diseases. Its lead product ZADAXIN is in several late-stage clinical trials for hepatitis B & C, malignant melanoma and liver cancer. In addition to ZADAXIN, the company's drug development opportunities include SCV-07, a potentially orally available therapy to treat viral and infectious diseases, and products to address the protein-based disorder that causes cystic fibrosis.
XOMA Ltd., headquartered in Berkeley, California, develops and manufactures antibody and other protein-based biopharmaceuticals for disease targets that include cancer, immunological and inflammatory disorders, and infectious diseases. XOMA's programs include collaborations relating Raptiva(TM) antibody for psoriasis, rheumatoid arthritis, psoriatic arthritis and other indications; NEUPREX (R)(rBPI21) for Crohn's disease and other indications; and on two biotherapeutic agents, CAB2 and MLN01, for certain vascular inflammation indications.
As a result of the re-ranking, Emisphere Technologies, Inc. (EMIS) EntreMed, Inc. (ENMD) will be removed from the Index
BigNick
Siamo solo noi
- Registrato
- 10/7/01
- Messaggi
- 10.951
- Punti reazioni
- 908
Vediamo oggi come reagisce ai dati
EntreMed Reports First Quarter 2003 Results
Wednesday May 14, 6:00 am ET
ROCKVILLE, Md., May 14 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD - News), a biopharmaceutical company focusing on the research and product development of small molecules, today reported results for the three months ended March 31, 2003.
(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )
Revenues for the first quarter 2003 were $514,000 versus $60,000 for the comparable period a year ago. The Company reported a net loss for the first quarter of ($3.7 million), or ($0.16) per share, compared with a net loss of ($14.5 million), or ($0.67) per share, for the same period last year. As of March 31, 2003, EntreMed had approximately $15 million in cash and short-term investments. EntreMed believes that this cash, combined with the net proceeds of its $10.25 million equity transaction completed on April 28, will fund planned activities well into 2004.
EntreMed President and Chief Operating Officer Neil Campbell commented, "EntreMed continues to strengthen the Company's financial position through a combination of managing resources prudently and accessing the capital markets when appropriate to execute our business plan, including the continued development of our small molecule and peptide programs, led by the clinical drug candidate Panzem®."
EntreMed will hold a conference call today at 11:00 am EDT to present its first quarter 2003 financial results. A live webcast of the conference call will be available online at www.entremed.com; please log onto EntreMed's website at least ten minutes prior to the start of the event and follow the instructions.
EntreMed Reports First Quarter 2003 Results
Wednesday May 14, 6:00 am ET
ROCKVILLE, Md., May 14 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD - News), a biopharmaceutical company focusing on the research and product development of small molecules, today reported results for the three months ended March 31, 2003.
(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )
Revenues for the first quarter 2003 were $514,000 versus $60,000 for the comparable period a year ago. The Company reported a net loss for the first quarter of ($3.7 million), or ($0.16) per share, compared with a net loss of ($14.5 million), or ($0.67) per share, for the same period last year. As of March 31, 2003, EntreMed had approximately $15 million in cash and short-term investments. EntreMed believes that this cash, combined with the net proceeds of its $10.25 million equity transaction completed on April 28, will fund planned activities well into 2004.
EntreMed President and Chief Operating Officer Neil Campbell commented, "EntreMed continues to strengthen the Company's financial position through a combination of managing resources prudently and accessing the capital markets when appropriate to execute our business plan, including the continued development of our small molecule and peptide programs, led by the clinical drug candidate Panzem®."
EntreMed will hold a conference call today at 11:00 am EDT to present its first quarter 2003 financial results. A live webcast of the conference call will be available online at www.entremed.com; please log onto EntreMed's website at least ten minutes prior to the start of the event and follow the instructions.
BigNick
Siamo solo noi
- Registrato
- 10/7/01
- Messaggi
- 10.951
- Punti reazioni
- 908
Re: Re: Vediamo oggi come reagisce ai dati
BigNick
non saprei, però nel pre sembra salireScritto da ffaiper
da quanto sono riuscito a capire é buona la rimestrale!!non ne ho capito molto per quanto riguarda i soldi in cassa vorrei sapere il tuo giudizio big nick!! ciao max
BigNick
ffaiper
nvediCOMEballaNASQAD
- Registrato
- 8/12/02
- Messaggi
- 1.583
- Punti reazioni
- 6
Re: sai....
complimenti big nick
beato te,avevo timore ke il nasdaq oggi andasse giu,infatti,ed(fino alle 17.00 lavoro in officina),ho messo un ordine,a +16% dal mio prezzo di riferimento e me la beccato!! megkio ke niente!Scritto da BigNick
io sono uno che si accontentaa..di un 42 %
BigNIck
complimenti big nick
BigNick
Siamo solo noi
- Registrato
- 10/7/01
- Messaggi
- 10.951
- Punti reazioni
- 908
Re: Re: sai....
Beato me una mazza, purtroppo non le ho prese
ciao
Scritto da ffaiper
beato te,avevo timore ke il nasdaq oggi andasse giu,infatti,ed(fino alle 17.00 lavoro in officina),ho messo un ordine,a +16% dal mio prezzo di riferimento e me la beccato!! megkio ke niente!
complimenti big nick
Beato me una mazza, purtroppo non le ho prese
ciao